

**Laurus Labs Limited**  
**Corporate Office**  
2<sup>nd</sup> Floor, Serene Chambers, Road No. 7  
Banjara Hills, Hyderabad - 500034, Telangana, India  
T +91 40 39804333 / 2342 0500 / 501  
F +91 40 3980 4320



**June 30, 2017**

To,

- 1. Gilead Sciences, Inc.**  
333 Lakeside Drive, Foster City  
California 94404, USA
- 2. Medicines Patent Pool**  
Chemin Louis-Dunant 17  
1202 Geneva, Switzerland

Dear Sirs,

**Sub:** Termination of License on API Basis for Products (i) Tenofovir Disoproxil Fumarate (TDF); (ii) Cobicistat (COBI); and (iii) Elvitegravir (EVG)

**Ref:** License Agreement dated 11<sup>th</sup> September 2014, executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Laurus Labs Limited.

In accordance with section 10.5 of the above License Agreement, Laurus Labs Limited hereby provides notice of termination of the license for the products - (i) Tenofovir Disoproxil Fumarate (TDF); (ii) Cobicistat (COBI); and (iii) Elvitegravir (EVG) with immediate effect.

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely,  
For Laurus Labs Limited

**Dr. Srihari Raju Kalidindi**  
**Executive Director**